药物联合逆转肿瘤细胞耐药的机制及研究进展  

Advances in the mechanism of drug combination to revers drug resistance in tumor cells

作　　者：张林曦 潘亚敏[1] ZHANG Linxi;PAN Yamin(Shuguang Clinical Medical College Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China)

机构地区：[1]上海中医药大学附属曙光临床医学院,上海201203

出　　处：《现代肿瘤医学》2020年第22期4008-4012,共5页Journal of Modern Oncology

基　　金：国家自然科学基金资助项目(编号:81774079)。

摘　　要：针对肿瘤细胞的特异性目前开发了各种治疗药物,但由于耐药机制的存在,最终限制了抗肿瘤药物的疗效。因此采用新颖的联合疗法,了解联合疗法的相互作用,通过这些相互作用来干扰肿瘤细胞生存或生长途径和它们之间建立的串扰,来逆转肿瘤细胞的耐药机制,是未来解决肿瘤细胞耐药性问题的关键点之一。本文就目前联合用药抗肿瘤细胞耐药性的研究进展作出系统回顾。Currently,various therapeutic drugs have been developed aiming at the specificity of tumor cells,but due to the resistance mechanism,the efficacy of anti-tumor drugs is still limited.Therefore,reversing the tumor cells'drug resistance mechanism is one of the keys to solving tumor cells in the future.In order to establish that,medical scholars are using the novel combination therapy.Nonetheless,they are also trying to understand the combination therapy's interaction,which interfere with the survival of tumor cells'growth pathways and the crosstalk established between them.This paper reviews the advances in the mechanism of the drug combination to reverse drug resistance in tumor cells.

关 键 词：肿瘤细胞 耐药 联合 逆转 

分 类 号：R730.5[医药卫生—肿瘤]